Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V3381 in chronic cough
ISRCTN66679782Phase 2Completed
- Sponsor
- Vernalis
- Start
- Oct 2009
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of indantadol in chronic cough and chronic idiopathic cough (CIC), sponsored by Vernalis. Primary endpoint: Objective cough frequency over 24 hours at 8 weeks compared with baseline. Started Oct 2009; status: completed.
02
Drugs
indantadol
03
Conditions
chronic coughchronic idiopathic cough (CIC)
Beyond the preview
Go deeper on ISRCTN66679782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66679782.